Tardive dyskinesia and developmental disabilities: An examination of demographics and topography in persons with dual diagnosis

British Journal of Developmental Disabilities

Volumn 46, Issue 2, 2000, Pages 119-130

  Matson, J L ^a   Bamburg, J W ^b   Mayville, E A ^b   Logan, J R ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PSYCHOTROPIC AGENT; RISPERIDONE; THIORIDAZINE;

ADULT; ARTICLE; BEHAVIOR DISORDER; DEMOGRAPHY; DEVELOPMENTAL DISORDER; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MENTAL DEFICIENCY; RATING SCALE; RISK FACTOR; SIDE EFFECT; SYMPTOMATOLOGY; TARDIVE DYSKINESIA; TOPOGRAPHY; UNITED STATES;

EID: 0033930467     PISSN: 09697950     EISSN: None     Source Type: Journal    
DOI: 10.1179/096979500799155711     Document Type: Article

References (21)

1. American Psychiatric Association. (1994). Diagnostic and Statistical Manual - Fourth Edition. Washington DC: APA.
2. Borthwick-Duffy, S. A. (1994), Epidemiology and prevalence of psychopathology in people with mental retardation. Journal of Consulting and Clinical Psychology, 62, 17-27.
3. Casey, D. E. and Keepers, G. A. (1988). Neuroleptic side effects: Acute extrapyramidal syndromes and tardive dyskinesia. In: Casey, D. E. and Christensen, A. V. (Eds.). Psychopharmacology: Current Trends. Berlin, Germany: Springer-Verlag.
4. Cohen, S., Khan, A., Zheng, Y. and Chiles, J. (1991). Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population. Acta Psychiatrica Scandinavica, 83, 234-237.
5. Davis, K. L., Berger, P. A. and Hollister, L. E. (1976). Tardive dyskinesia and depressive illness. Psychopharmacology Communications, 2, 125-130.
6. Fenton, W. S., Wyatt, R. J. and McGlashan, T. H. (1994). Risk factors for spontaneous dyskinesia in schizophrenia. Archives of General Psychiatry, 51, 643-650.
7. Jeste, D. V. and Caliguiri, M. P. (1993). Tardive dyskinesia. Schizophrenia Bulletin, 19, 303-314.
8. Jeste, D. V. and Wyatt, R. J. (1982). Understanding and Treating Tardive Dyskinesia. New York, NY: Guilford Press, 1982.
9. Kalachnik, J. (1983). Tardive dyskinesia and the mentally retarded: a review. In: S. E. Bruening (Ed.). Advances in Mental Retardation and Developmental Disabilities, vol 2, New York: Raven Press.
10. Kane, J. M., Woerner, M. and Liberman, J. (1985). Tardive dyskinesia: Prevalence, incidence and risk factors. In: D. E. Casey, T N. Chase, A. V. Christensen and J. Gerlach (Eds.). Dyskinesia: Research and Treatment. Berlin, Germany: Springer-Verlag.
11. McCreadie, R. G. and Ohaeri, J. U. (1994). Movement disorder in never and minimally treated Nigerian schizophrenic patients. British Journal of Psychiatry, 164, 184-189.
12. Menza, M. A., Grossman, N., Van Horn, M., Cody, R. and Forman, N. (1991). Smoking and movement disorders in psychiatric patients. Society of Biological Psychiatry, 30, 109-115.
13. Mukhergee, S., Rosen, A. M., Caracci, G. and Shukla, S. (1986). Persistent tardive dyskinesia in bipolar patients. Archives of General Psychiatry, 43, 342-346.
14. Richardson, M. A., Haugland, G., Pass, R. and Craig, T. J. (1986). The prevalence of tardive dyskinesia in a mentally retarded population. Psychopharmacology Bulletin, 22, 243-249.
15. Rinck, C. (1998). Epidemiology and psychoactive medication. In: S. Reiss and M. G. Aman (Eds.). Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: The Ohio State University Nisonger Center.
16. Rosenbaum, A. H., Niven, R. G., Hanson, N. P. and Swanson, D. W. (1977). Tardive dyskinesia: Relationship with primary affective disorder. Disorders of the Nervous System, 38, 423-427.
17. Sprague, R. L. and Kalachnik, J. E. (1991). Reliability and a total score cutoff for the Dyskinesia Identification System: Condensed User Scale (DISCUS) with mentally ill and mentally retarded populations. Psychopharmacology Bulletin, 27, 51-58.
18. Sramek, J., Roy, S., Ahrens, T., Pinanong, P., Cutler, N. R. and Pi, E. (1991). Prevalence of tardive dyskinesia among three ethnic groups of psychiatric patients. Hospital and Community Psychiatry, 42, 590-592.
19. Wilson, J. G., Lott, R. S. and Tsai, L. (1998). Side effects: Recognition and management. In: S. Reiss and M. G. Aman (Eds.). Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook. Columbus, OH: The Ohio State University Nisonger Center.
20. Yassa, R. and Jeste, D. V. (1992). Gender differences in tardive dyskinesia: A critical review of the literature. Schizophrenia Bulletin, 18, 701-715.
21. yassa, R., Nair, V. and Schwartz, G. (1984). Tardive dyskinesia: A two-year follow-up study. Psychosomatics, 25, 852-855.